The Global Birch Allergy Market is projected to reach USD 2.60 Bn by 2032, with a CAGR of 9.8% from 2025. Factors include rising awareness, diagnosis, treatment advancements, and healthcare spending. North America will lead, and Asia Pacific is an emerging market. Rising prevalence of birch allergies and seasonal allergic rhinitis drive market growth.

Pharmacotherapy dominates the industry, adults comprise 34.2% of the market, and oral administration accounts for nearly half of the market share. North America leads with 40% market share, while Asia Pacific is expected to capture 24.2% by 2025.

Climate change and urbanization extend pollen seasons, increasing birch allergy cases. Treatment costs and side effects may hinder market growth. Advances in allergen-specific immunotherapies like SLIT and SCIT offer growth opportunities.

Emerging trends include increased awareness, personalized medicine, and R&D for novel biologics. Key players include Regeneron, ALK-Abelló, Stallergenes Greer, and more. Recent developments include positive Phase 3 trials and new EU-approved treatments.

Market segmentation includes type, age group, route of administration, distribution channel, end user, and region. Related reports cover allergy shots, immunotherapy, and treatment markets. Trusted partners include Worldwide Market Reports, Coherent MI, and Stratagem Market Insights.

Read more at GlobeNewswire: CAGR of 9.8% and Value